Quick Overview
- AIM ImmunoTech shares jumped 97.18% Wednesday following Japanese patent approval for its cancer therapy approach
- The approved patent protects the use of Ampligen combined with checkpoint inhibitor drugs for various cancer types, with emphasis on pancreatic cancer
- Patent protection extends through December 20, 2039
- The company previously secured comparable patents in the United States and Netherlands
- AIM intends to pursue orphan drug status in Japan for Ampligen as a pancreatic cancer therapy
AIM ImmunoTech (AIM) shares experienced a dramatic rally on Wednesday, climbing nearly 100% after receiving patent approval from Japan’s Patent Office for a cancer treatment methodology that combines its Ampligen drug with checkpoint inhibitor medications.
$AIM < $1 – AIM ImmunoTech
Announces Final Approval of Novel Cancer Therapy Patent in Japan, covering pancreatic cancer
— John Zidar aka/ Stock Wizard (@JohnZidar) March 18, 2026
Shares closed the session up 97.18%, building on a year-to-date increase of 24.11%. However, the stock remains down 94.21% from levels seen twelve months ago.
Trading activity surged dramatically during the session. Approximately 10.6 million shares exchanged hands Wednesday, representing a significant jump from the typical three-month average of roughly 2.7 million shares daily.
The intellectual property protection, initially awarded in September 2025, successfully completed a mandatory six-month challenge period before receiving final status. The patent encompasses multiple cancer indications, placing particular emphasis on pancreatic malignancies.
Projections indicate both the United States and Japan will experience increasing pancreatic cancer incidence rates through 2030. The company characterized this disease as “an extremely lethal and unmet global health problem.”
The Japanese intellectual property protection remains enforceable until December 20, 2039, providing AIM with an extended timeframe to advance and potentially bring its therapeutic approach to market in Japan.
Expanding Patent Rights Across Markets
The company previously secured patent protection in the United States covering Ampligen’s use alongside anti-PD-L1 antibody treatments, plus a Netherlands patent for Ampligen combined with checkpoint blockade medications — including branded therapies Keytruda, Opdivo, and Imfinzi.
Japan’s approval represents the third significant market addition to this intellectual property collection, with AIM indicating plans to further strengthen its IP position in the country.
AIM CEO Thomas Equels stated: “Securing this critical patent in a key global market is just the latest step in AIM’s robust development and commercialization strategy.”
The biotechnology firm is simultaneously working toward orphan drug designation in Japan specifically for Ampligen in treating pancreatic cancer, which would provide additional intellectual property advantages.
Financial Health Raises Red Flags
Despite positive patent developments, AIM’s financial condition presents substantial concerns. The company operates with a market capitalization near $3 million and reported revenue of only $0.11 million.
Operating margin registers at -13,006%, while net margin stands at -14,062%. The current ratio of 0.64 indicates potential liquidity challenges ahead.
The company’s Altman Z-Score registers -120.53, positioning AIM squarely within the financial distress category. Additionally, a Beneish M-Score of 1.8 suggests potential accounting irregularities worth monitoring.
Institutional investors hold merely 3.31% of outstanding shares. Company insiders own 13.41% of the equity.
With a beta of 2.16, AIM demonstrates significantly higher volatility compared to broader market indices. Wednesday’s dramatic price movement exemplified this characteristic.
Prior to the patent announcement, the RSI reading of 38.02 suggested the stock was approaching oversold conditions.
Ampligen lacks regulatory approval across most global markets, though it has received authorization for treating severe Chronic Fatigue Syndrome in Argentina.
With the Japanese patent opposition window now officially closed, the company can advance its commercialization strategy for the Asian market.
The post AIM ImmunoTech (AIM) Stock Soars Nearly 100% on Japanese Cancer Treatment Patent Approval appeared first on Blockonomi.
